Cite
HARVARD Citation
Llavero, N. et al. (n.d.). 522OMutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype. Annals of oncology. p. . [Online].